Introduction
============

Anatomically, inhibitory neocortical networks are outweighed by their excitatory counterparts by about 1:4, yet, if the integrity of inhibitory circuits is degraded, even a small amount, the properties of an entire network can be profoundly affected ([@bib13]; [@bib12]; [@bib14]; [@bib34]; [@bib48]; [@bib20]). Detailed studies on the intrinsic and synaptic properties of the inhibitory interneurons and their influence on the pre- as well as postsynaptic gain of the target cells are imperative for the evaluation of their contribution to normal development as well as pathological disorders. In the auditory cortex (ACx), for example, activation of γ-amino butyric acid (GABA) circuits leads to sharpening of onset responses and excitatory receptive field properties ([@bib50]; [@bib75]; [@bib21]). Such properties and the percepts that they support, such as speech discrimination in background noise, can be compromised by hearing loss, and this, in part, is due to a selective decline in inhibitory synapse function that shapes sound-driven response properties ([@bib11]).

The strength of inhibitory postsynaptic currents (IPSCs) represents, in part, the number of synaptic GABA~A~ receptors and the specific array of subunits ([@bib56]; [@bib52], [@bib53]). Modulation of the subunit expression and distribution, therefore, has profound consequences on the development and plasticity of inhibitory synapses ([@bib18]; [@bib24]) and neural excitability under both physiological and pathophysiological conditions. In the mammalian brain, the most abundant pentameric receptors are comprised of α, β, and γ subunits; the most common stoichiometry within the neocortex is 2α:2β:1γ ([@bib62]; [@bib47]; [@bib38]).

The developmental expression of specific receptor subunits, and their distribution on a single neocortical or hippocampal neuron, can impart distinct functional properties. For example, experiments in "knock-in" mice show that while α1 subunits may participate in cortical plasticity, α2 subunits regulate neuronal firing ([@bib19]), presumably due to their abundance at synapses on the axon initial segment of pyramidal cells ([@bib51]; [@bib22]). The profound changes in developmental expression of specific subunits ([@bib39]) may also underlie the ontogenic changes in inhibitory postsynaptic current (IPSC) kinetics ([@bib73]; [@bib3]; [@bib48]; [@bib5]; [@bib26]; [@bib49]; [@bib27]).

Experimental manipulations have shown that inhibitory neurotransmission is a critical determinant of neuronal network gain, suggesting that network properties are shaped by GABAergic transmission ([@bib32]; [@bib10]; [@bib68]). Prior studies in the developing ventral auditory brain stem and midbrain have shown that the loss of cochlear activity for 1 to several days in vivo leads to a reduction of inhibitory synaptic gain due to diminished inhibitory postsynaptic potential (IPSP)/IPSC amplitudes and depolarized inhibitory reversal potential/current ([@bib36]; [@bib69]). In the inferior colliculus (IC) neurons, such weakening of IPSCs is characterized by reduced inhibitory conductance and a compromised chloride cotransporter function ([@bib69]; [@bib71]). Furthermore, electrophysiological and quantitative electron microscopic (EM)-immunogold data show that developmental sensorineural hearing loss (SNHL) leads to a significant enhancement in excitatory synapse function in L2/3 pyramidal neurons of the ACx mediated by both α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and *N*-methyl-[D]{.smallcaps}-aspartic acid (NMDA) receptors ([@bib37]).

The current study addresses the question whether early auditory experience influences the development of GABAergic transmission. Our data show that the amplitudes of IPSCs decline following developmental SNHL. This was accompanied by the inability of the GABA~A~ receptor subunits, α1 and β2/3, to respond to specific agonists. Moreover, increased frequency of spontaneous (s) IPSCs and miniature (m) IPSCs indicate parallel alterations at the presynaptic locus. Anatomically, quantitative EM-immunocytochemical assays reveal that presynaptic glutamic acid decarboxylase (GAD) increased and postsynaptic β2/3 subunit immunogold counts decreased following SNHL (Sarro E, Kotak VC, Sanes DH, Aoki C, unpublished data). Additionally, IPSCs from animals before hearing onset shared characteristics similar to SNHL IPSCs, including insensitivity to the subunit-specific agonists. Thus, SNHL may prevent the normal maturation of GABAergic transmission in the ACx.

Material and Methods
====================

Surgery for SNHL
----------------

All protocols were reviewed and approved by New York University Institutional Animal Care and Use Committee. As described previously ([@bib70]), cochlear ablations were performed on gerbil (*Meriones unguiculatus*) pups at postnatal day 10 (P10), just before the onset of response to airborne sound. Gerbil pups were anesthetized (methoxyflurane), which was assessed by a lack of toe-pinch response. Each cochlea was then rapidly removed with a forceps. The wound was sealed, the pups were placed on a heating pad, and then transferred to the breeding pair. Pups were then reared for 6--9 days with their parents under conditions identical to those for control pups. The age of surgery was chosen based on evidence that anteroventral cochlear nucleus cell number is unaffected by cochlear ablation after P9 ([@bib65]). Cochlea removal was confirmed post mortem by opening each cochlea under a dissecting microscope and finding the absence of cochlear tissue but gel foam in its place.

Thalamocortical Brain Slice Recordings and Pharmacology
-------------------------------------------------------

Horizontal thalamocortical brain slices that retained the afferent projection from ventral medial geniculate nucleus (MGv) to the ACx (thalamorecipient cortex, ACx; [@bib37]) were generated from P8--20 gerbils. The artificial cerebrospinal fluid (ACSF) contained (in mM): 125 NaCl, 4 KCl, 1.2 KH~2~PO4, 1.3 MgSO4, 26 NaHCO~3~, 15 glucose, 2.4 CaCl~2~, and 0.4 [L]{.smallcaps}-ascorbic acid (pH 7.3 when bubbled with 95% O~2~--5% CO~2~). ACSF was superfused in the recording chamber at 3 mL/min at 32 ±1 °C. Whole-cell recordings were obtained from layer 2/3 pyramidal neurons that were located in the thalamorecipient cortex. Neurons were visually identified under infrared differential interface contrast (IR-DIC) optics prior to obtaining a GΩ seal. The location of individual neuron cell bodies varied from 125 to 400 μm from the pial surface. The data in this paper were collected from 104 recordings from control (*n* = 43), SNHL (*n* = 45), and prehearing (*n* = 16) neurons.

GABAergic Activity and Pharmacological Manipulations
----------------------------------------------------

To characterize GABA~A~ receptor--mediated sIPSCs and minimum-evoked (me) IPSCs whole-cell voltage-clamp recordings were made at a bandwidth of 10 kHz. The internal patch solution contained (in mM): 100 KCl, 40 K-gluconate, 10 NaCl, 10 \[4-(2-hydroxyethyl)-1-piperazineethanesulfonic free acid\] (HEPES), 4 MgATP, 0.1 ethyleneglycol-bis(2-aminoethylether)-*N*,*N*,*N*',*N*'-tetraacetic acid (EGTA), and 5 lidocaine derivative QX-314 (pH = 7.2 with KOH). Bipolar platinum wire stimulating electrodes were placed in the MGv and in upper cortical layer 4 (L4) approximately 100 μm from the recording site to stimulate the thalamocortical and intracortical pathways, respectively. These stimulating electrodes were fabricated from 0.004" diameter teflon-coated platinum wires (A-M systems, Carlsborg, WA) inserted into an approximately 2"-long double-barrel glass electrode. The tips of the wires were bared of the teflon coat (the exposed tip was 0.002" diameter).

To isolate inhibitory GABAergic activity, 6,7-Dinitroquinoxaline-2,3-dione (DNQX) (20 μM) and 2-amino-5-phosphonopentanoate (AP-5) (50 μM) were added to the superfusing ACSF to block AMPA and NMDA receptors, respectively. The drugs were applied for a minimum of 8 min before recording inhibitory currents. For acquiring sIPSCs and mIPSCs, at least 10 sweeps of 30-s duration each were acquired for each neuron at holding potential close to the resting membrane potential; *V*~HOLD~ = −60 mV ([@bib37]). The mIPSC recordings were obtained in the presence of 1 μM tetrodotoxin (TTX).

To examine whether the strength of putative monosynaptic inhibitory connections was altered following SNHL, me-IPSCs were recorded in normal ACSF in voltage-clamp conditions at *V*~HOLD~ = −60 mV. Incremental stimulus intensities were delivered to L4 at 0.1 Hz until an evoked IPSC was discernible ([Fig. 2A](#fig2){ref-type="fig"}). Stimulation at this intensity produced ≥50% failures in eliciting IPSCs. The absolute stimulus intensity varied approximately 5% between preparations and ages. Increasing the minimal intensity by more than 5% decreased the failure rate and increased the IPSC amplitude and possible polysynaptic innervations. Therefore, the minimal stimulation intensity was kept constant throughout each recording. The failure rates were not analyzed.

The function of the 2 GABA~A~ receptor subunits was tested by the use of agonists. Zolpidem (100 nM, Tocris Biosciences, Bristol, UK) was applied to test for the presence of the α1 subunits, and loreclezole (10 μM, Tocris Biosciences) was applied to test for the presence of the β2/3 subunits. These agents were added to ACSF and bath applied for at least 15 min before recording the effect on sIPSC durations. These data were separately acquired in 2 second traces; at least 50 traces were recorded per neuron. Thus, they do not constitute a part of the sIPSC data on amplitudes and frequency recorded before. To validate that the recorded postsynaptic currents (sIPSCs, mIPSCs, and me-IPSCs) were due to GABA~A~ receptor activity, bicuculline (20 μM, BIC methoiodide; Sigma, St Louis, MO) or GABAzine (500 nM-1μM, Tocris Biosciences) was applied at the end of some experiments (*n* = 6).

Data Collection and Analysis
----------------------------

Data were collected using a Macintosh G4 running a custom-designed IGOR (WaveMetrics, v6.0) macro called SLICE (Kotak et al. 2001). Evoked synaptic potentials and currents were analyzed off-line using a 2nd IGOR macro called SLICE ANALYSIS. Analysis was restricted to IPSC amplitudes that were ≥6 pA as these events could be reliably identified in baseline noise. sIPSC durations were manually analyzed off-line using the SLICE ANALYSIS program, by superimposing 1-ms vertical grids on traces. The time between the onset of the falling phase of the sIPSC and the return of the decay phase of the IPSC to the original baseline was considered as the total duration (ms). Any sIPSCs (2 or more) that summated before a single sIPSC decay returned to baseline were not considered in this analysis. To ascertain changes of sIPSC durations following experimental and pharmacological manipulations, analysis was restricted to IPSCs collected separately, majority (95%) of whose amplitudes varied between 20 and 80 pA (above). Thus, we biased this analysis such that there was no statistical difference between the control and SNHL sIPSC amplitudes (ca. 40 pA). This strategy discounted the amplitude-dependent fluctuations in sIPSC kinetic properties. Statistical tests (analysis of variance \[ANOVA\], Students\' *t*-test for normally distributed data, or Wilcoxon nonparametric test for data that were not normally distributed) were performed using statistical software (JMP, SAS Institute, Cary, NC).

Results
=======

Hearing Loss Alters sIPSCs and mIPSCs
-------------------------------------

To determine whether hearing loss altered the inhibitory network properties, we 1st recorded sIPSCs under voltage-clamp conditions at a holding potential of −60 mV after blocking ionotropic glutamate receptor transmission. The results showed that the mean sIPSC frequency was increased while the mean amplitude was decreased significantly in SNHL neurons. (sIPSC frequency, mean ± standard error of the mean \[SEM\]: control, 2 ± 0.2 Hz vs. SNHL, 4.6 ± 0.2 Hz; *t*-test, *t* = 7.1; degrees of freedom \[df\] = 22, *P* = 0.0001; sIPSC amplitude, mean ± SEM: control, 28 ± 2 pA vs. SNHL, 19 ± 2 Hz; *t*-test, *t* = 2.6; df = 20, *P* = 0.01; [Fig. 1](#fig1){ref-type="fig"}). To further test whether these changes persisted in complete absence of presynaptic action potentials, TTX (500 nM) was added at the end of the recording session in some experiments. These results were comparable to sIPSCs, in that higher mIPSC frequency was accompanied by significantly reduced amplitudes for SNHL neurons (mIPSC frequency, mean ± SEM: control, 2.2 ± 0.4 Hz vs. SNHL, 5.2 ± 0.4 Hz; *t*-test, *t* = 4.5; df = 9, *P* = 0.002; mIPSC amplitude, mean ± SEM: control, 35 ± 3 pA vs. SNHL, 19 ± 3 Hz; *t*-test, *t* = 3.4; df = 9, *P* = 0.01; recordings not shown).

![SNHL sIPSC amplitudes are smaller and frequency is higher. (*A, B*) The top panel (*A*) shows 2 sweeps of sIPSCs recorded in the presence of DNQX and AP-5 for 30 s each in a P17 control neuron (*A*) and an age-matched SNHL neuron (*B*) at a holding potential of −60 mV. In both cases, each recording was acquired 1 min apart. Note that amplitudes of sIPSCs in the SNHL neuron are smaller, whereas the frequency is higher. In both control as well as SNHL recordings, addition of 1 μM GABAzine eliminates sIPSCs, showing that they were mediated by the activation of GABA~A~ receptors. (*C*) Bar graphs summarizing the mean amplitude and frequency of sIPSCs recorded from 11 normal and 12 SNHL neurons. Note that the amplitude of mean sIPSCs is smaller in SNHL neurons (left panel, filled bar), whereas the mean frequency of sIPSCs is greater in SNHL neurons (right panel, filled bar). In this and all subsequent figures, asterisks indicate that the differences are significant (for statistics, see Results).](cercorbhm233f01_lw){#fig1}

Hearing Loss Perturbs sIPSC Kinetics
------------------------------------

Among other factors, sIPSC kinetic properties reflect underlying function of an array of GABA~A~ receptor subunits. To measure durations, we used hundreds of control and SNHL sIPSCs that were separately recorded in 2-s sessions. To exclude the sIPSC amplitude-based variation in durations, we measured sIPSC durations of comparable amplitudes with an average of about 40 pA. This analysis showed that sIPSC durations were significantly longer in the SNHL group. (sIPSC duration, mean ms ± SEM: control, 58 ± 4 vs. SNHL, 89 ± 4; *t = *5.6; df = 19, *P = *0.0004; [Fig. 2](#fig2){ref-type="fig"}). The effect of hearing loss on sIPSC duration was thus independent of amplitudes because sIPSC amplitudes did not differ between the 2 groups; hence, it is discounted as a factor for this analysis (sIPSC amplitudes, mean pA ± SEM: control 39.6 ± 2, SNHL, 40 ± 3.3, *P* = 0.9).

![SNHL sIPSC durations are long. (*A*) Two sweeps of sIPSCs recorded for 2 s each in a P17 control (top, 2 gray traces) and an age-matched SNHL neuron (bottom, black traces) at a holding potential of −60 mV. Each recording was acquired 10 s apart. Note that the durations of sIPSCs in the SNHL neuron are longer. (*B*) Distribution of all sIPSCs durations, 528 from 10 control neurons and 582 from 10 SNHL neurons, showing that the sIPSCs durations in SNHL neurons are significantly longer.](cercorbhm233f02_ht){#fig2}

Hearing Loss Decreases me-IPSCs
-------------------------------

Our previous study showed that hearing loss significantly enhanced putative monosynaptic excitatory input originating from the MGv to L2/3 ([@bib37]). To determine whether the strength of putative monosynaptic inhibitory inputs from GABAergic interneurons to L2/3 pyramidal neurons was affected by SNHL, me-IPCSs (me-IPSCs) were recorded in the presence of blockers of ionotropic glutamate receptors, DNQX and AP-5. Over 100 intracortically evoked recordings were obtained from each neuron, of which about 50% responses contained an IPSC. The amplitudes of the 6 smallest me-IPSCs were averaged for each neuron. Comparison of these me-ISPCs revealed that activation of such putative unitary afferents produce significantly reduced IPSC amplitudes in SNHL neurons (me-IPSC amplitudes, mean pA ± SEM: normal, 14 ± 1.9 vs. SNHL, 7.7 ± 0.8; Wilcoxon\'s test, ν^2^ = 6.4; df = 20, *P = *0.01; [Fig. 3](#fig3){ref-type="fig"}).

![SNHL me-IPSC amplitudes are smaller and durations are longer. (*A*) Intracortical me-IPSCs were recorded in voltage clamp at *V*~HOLD~ of −60mV in the presence of ionotropic glutamate receptor blockers, DNQX and AP-5. me-IPSCs were elicited by stimulating L4 approximately 100 μm away from the L2/3 recording site at incremental intensities until the failures were replaced by responses. The intensity at which minimum IPSCs were discernible from failed responses (gray traces) was then chosen for successive recordings (black traces). Such minimal stimulation intensity produced a failure rate of 50% or more. (*B*) With the same method, note that me-IPSCs recorded from an age-matched SNHL neuron are smaller and longer (black traces). (*C, D*) Bar graphs summarizing the mean amplitude and duration of me-IPSCs recorded from 10 normal and 11 SNHL neurons. The amplitude of mean me-IPSCs is smaller in SNHL neurons (top panel, right, filled bar), whereas the mean duration of near me-IPSCs is longer in SNHL neurons (bottom, right panel, filled bar).](cercorbhm233f03_ht){#fig3}

Because the duration of sIPSCs differed, we acquired additional data to compare me-IPSC durations. For this, IPSCs were examined slightly above minimum thresholds for control and SNHL neurons for consistent kinetic measurements. The stimulus intensity was adjusted about 5% above that which produced a 50% failure rate for these experiments. IPSC amplitudes between 15 and 40 pA were recorded, and thus, the mean amplitude did not differ between the 2 groups (near me-IPSC amplitudes, mean pA ± SEM: control, 20.5 ± 8.7 vs. SNHL, 19.1 ± 2.1, df = 13, *P* = 0.7). However, the IPSC durations were significantly longer in SNHL neurons (IPSC duration, mean ms ± SEM: control, 92.5 ± 14.5 vs. SNHL, 156.5 ± 20.4; *t* = 2.55; df = 13, *P = *0.025; [Fig. 3](#fig3){ref-type="fig"}).

SNHL May Disrupt α1 and β2/3 Subunit Function
---------------------------------------------

If the hearing loss--mediated increase in sIPSC duration involves a change in the expression of GABA~A~ receptor subunits, then the efficacy of specific subunit agonists should be perturbed. To test this idea, agonists for GABA~A~ receptor subunits known for their high affinity to the benzodiazapine-binding site (zolpidem, α1 agonist) or an anticonvulsant site (loreclezole, β2/3 agonist) were employed. Whereas zolpidem (100 nM) significantly prolonged sIPSC durations in control neurons, the agonist failed to enhance sIPSC durations in SNHL neurons (control sIPSC durations, mean ms ± SEM: before zolpidem, 69 ± 4 vs. after zolpidem, 114 ± 10; *t* = 5.6; df = 9, *P = *0.003; SNHL sIPSC durations mean ms ± SEM, before zolpidem, 94 ± 6 vs. after zolpidem, 102 ± 7, *t* = 0.8, df = 9, *P = *0.4; [Fig. 4](#fig4){ref-type="fig"}). Similarly, bath application of the β2/3 subunit agonist, loreclezole (10 μM), significantly lengthened sIPSC durations in control neurons but did not significantly affect sIPSC durations in SNHL neurons (control sIPSC durations, mean ms ± SEM: before loreclezole, 49 ± 2 vs. after loreclezole, 97 ± 5, Wilcoxon\'s test, χ^2^ = 6.8; *P = *0.009; SNHL sIPSC durations, mean ms ± SEM: before loreclezole, 83 ± 3 vs. after loreclezole, 94 ± 12, Wilcoxon\'s test, χ^2^ = 0.01, *P* = 0.9; [Fig. 5](#fig5){ref-type="fig"}).

![SNHL disrupts α1 subunit function. (*A*) Two sweeps of sIPSCs recorded for 2 s each in a P17 control (top, 2 gray traces) at a holding potential of −60 mV. Each recording was acquired 10 s apart. Note that GABA~A~ receptor α1 subunit--specific agonist, zolpidem, prolongs sIPSC durations (bottom, 2 black traces). (*B*) Note that in an age-matched SNHL neuron, zolpidem application does not produce an increase in sIPSC durations. (*C, D*) Distribution of all sIPSCs durations, 470 from 5 control neurons and 572 from 5 SNHL neurons, showing that the sIPSCs durations are significantly prolonged by zolpidem treatment in control neurons but not in SNHL neurons. Horizontal bars indicate mean sIPSC durations.](cercorbhm233f04_ht){#fig4}

![SNHL disrupts β2/3 subunit function. (*A*) Two sweeps of sIPSCs recorded for 2 s each in a P17 control (top, 2 gray traces) at a holding potential of −60 mV. Each recording was acquired 10 s apart. Note that GABA~A~ receptor β2/3 subunit--specific agonist, loreclezole, prolongs sIPSC durations (bottom, 2 black traces). (*B*) Note that in an age-matched SNHL neuron, loreclezole application does not produce an increase in sIPSC durations. (*C, D*) Distribution of all sIPSCs durations, 564 from 5 control neurons and 608 from 5 SNHL neurons, showing that the sIPSCs durations are significantly prolonged by loreclezole application in control neurons but not in SNHL neurons. Horizontal bars indicate mean sIPSC durations.](cercorbhm233f05_ht){#fig5}

We therefore tested the hypothesis that SNHL may perturb the maturation of processes that underlie shortening of sIPSC durations following hearing onset. Additional recordings from animals before hearing onset (prehearing; P8--10) were therefore performed. The results showed that the sIPSC durations resembled the prolonged duration sIPSCs in SNHL neurons, when compared with controls. A 3-way comparison of means revealed that there was no significant difference between the sIPSC durations between SNHL and prehearing neurons, while the control sIPSC duration differed significantly from both groups (ANOVA, *F* = 15.2, df = 27; sIPSC durations, mean ms ± SEM: prehearing, 90.4 ± 6.5 vs. SNHL, 89 ± 4, *t* = 0.2, df = 17, *P* = 0.8; prehearing, 90.4 ± 6.5 vs. control, 59 ± 3.8; *t* = 4.1, df = 17, *P* = 0.0005, [Fig. 6](#fig6){ref-type="fig"}). This effect was independent of the amplitudes of sIPSCs (ANOVA, *F* = 0.2, df = 20, *P* = 0.8). Recordings of near me-IPSCs from prehearing neurons also showed that the durations were similar to SNHL me-IPSCs (IPSC durations, mean ms ± SEM: prehearing, 154.8 ± 19.5 vs. SNHL, 156.5 ± 20.4, *t* = 0.061, df = 13, *P* = 0.95).

![Prehearing IPSC durations are long. (*A*) Two sweeps of sIPSCs recorded for 2 s each in a P17 SNHL (top, 2 gray traces, taken from [Figure 2](#fig2){ref-type="fig"}) and a P10 prehearing neuron (bottom, 2 black traces) at a holding potential of −60 mV. Each recording was acquired 10 s apart. Note that the durations of sIPSCs in the prehearing neuron are long as in the SNHL neuron. (*B*) Distribution of all sIPSCs durations, 582 from 10 SNHL neurons and 469 from 8 prehearing neurons, showing the close resemblance between the sIPSC durations of prehearing and SNHL neurons. For comparison, see control sIPSC durations in [Figure 2](#fig2){ref-type="fig"}.](cercorbhm233f06_ht){#fig6}

To further test whether the reduced sensitivity of the SNHL sIPSCs to the α1 and β2/3 subunit agonists reflects an immature state, the agents were tested in prehearing neurons. Similar to SNHL, sIPSCs from prehearing animals did not show a significant change in duration after zolpidem or loreclezole applications (prehearing sIPSC durations, mean ms ± SEM; before zolpidem, 82.5 ± 4.3 vs. after zolpidem, 84.2 ± 6.0, *t*-test, *t* = 0.2, df = 7, *P = *0.8; before loreclezole, 79.0 ± 3.8 vs. after loreclezole, 90.0 ± 7.4, *t*-test, *t* = 1.3, df = 7, *P = *0.2; [Fig. 7](#fig7){ref-type="fig"}).

![Prehearing IPSC durations are insensitive to α1 and β2/3 subunit agonists. (*A*) Two sweeps of sIPSCs recorded for 2 s each in a P10 prehearing neuron (top, 2 gray traces) at a holding potential of −60 mV. Each recording was acquired 10 s apart. Note that the GABA~A~ receptor α1 subunit--specific agonist, zolpidem, does not prolong sIPSC durations (2 black traces). (*B*) Note that in another age-matched prehearing neuron, the application of the β2/3 agonist, loreclezole, does not prolong sIPSC durations. (*C, D*) Distribution of all sIPSC durations, from all prehearing neurons showing that the sIPSCs durations are not prolonged by zolpidem (581 sIPSCs from 4 neurons) or loreclezole (544 sIPSCs from 4 neurons). This result is similar to that obtained for SNHL neurons (see [Figs 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}).](cercorbhm233f07_ht){#fig7}

[Figure 8](#fig8){ref-type="fig"} is a schematic diagram summarizing the present findings on GABAergic transmission following SNHL, along with our previous findings on changes depicting heightened intrinsic and excitatory synaptic properties ([@bib37]) and 2 changes assayed at an EM-immunocytochemical level (Sarro E, Kotak VC, Sanes DH, Aoki C, unpublished data).

![Summary sketch of a L2/3 SNHL pyramidal neuron. This sketch highlights the present findings that hearing loss leads to alterations in inhibitory synaptic properties (top right panel, gray). Further, they accompany coadjustments in the passive and active intrinsic (bottom panel) and excitatory synaptic properties (bottom left panel). An upward arrow indicates increased whereas a downward arrow indicates decreased function. For example, SNHL caused a rise in resting membrane potential (*V*~REST~), firing properties, and input resistance (*R*~INPUT~; bottom panel; [@bib37]). For thalamocortical synapses, SNHL decreased the release probability (mEPSC frequency), whereas increasing mEPSC and thalamically evoked minimum-EPSC amplitudes and enhancing current carried by the NR2B subunits of the NMDA receptor (left panel). In contrast, the present study shows increased GABA release probability (higher sIPSCs and mIPSCs frequency) is accompanied by a decrease in sIPSC and me-IPSC amplitudes. Further, an inability of α1 and β2/3 subunit--specific agonists to alter sIPSCs recorded from SNHL and prehearing neurons sugests an arrest in the maturation of GABAergic transmission. The bottom right panel (dashed box) displays an observation derived from EM-immunocytochemistry (Sarro E, Kotak VC, Sanes DH, Aoki C, unpublished data) that postsynaptic β2/3 subunit distribution is disrupted. In addition, the presynaptic terminals may synthesize/release more GABA. The cumulative outcome of such robust homeostatic alterations following hearing loss may adjust the cortical network at a new set point in anticipation that peripheral activity will be restored.](cercorbhm233f08_ht){#fig8}

Discussion
==========

Deafness and GABAergic Properties
---------------------------------

Despite the strides made by behavioral and by in vivo physiology experiments, we are just beginning to understand the biophysical and synaptic alterations in the ACx that attend moderate or severe hearing loss. A previous report demonstrated that SNHL elevates excitability in L2/3 pyramidal neurons as reflected by changes in the passive membrane properties, increased thalamocortical excitatory drive, and diminished maximum-evoked IPSPs ([@bib37]). A fundamental question is whether inhibitory synapse function is altered at both pre- and postsynaptic loci. The present study shows that SNHL prevents the normal maturation of presynaptic release and postsynaptic GABA receptor function. Specifically, while the presynaptic terminals may release GABA more frequently ([Fig. 1](#fig1){ref-type="fig"}), the diminished amplitudes of unitary afferent-evoked inhibitory currents indicate inadequate postsynaptic GABA~A~ receptor activation ([Figs 1--3](#fig1 fig2 fig3){ref-type="fig"}, [@bib14]; [@bib52]). Futhermore, prolonged sIPSCs and evoked IPSCs, resembling those recorded in prehearing animals (P10), suggest that SNHL prevents the maturation of inhibitory synaptic properties. These altered IPSC kinetics are well correlated with the diminished efficacy of the α1 and β2/3 subunit--specific agonists in SNHL neurons ([Figs 4](#fig4){ref-type="fig"}--[5](#fig5){ref-type="fig"}) and prehearing neurons ([Fig. 7](#fig7){ref-type="fig"}). We argue that hearing experience is critical for the emergence of mature pre- and postsynaptic properties of GABAergic transmission in the ACx, and this involves key subunits integral to the postsynaptic GABA~A~ receptors.

Complete hearing loss is expected to affect endogenous patterns of activity across the ascending auditory pathway and key integrating elements in the brain stem, midbrain, and thalamus. For example, prior to the onset of hearing, gerbil IC neurons display spontaneous activity ([@bib35]). Maintained discharge at the level of the eighth nerve and ventral cochlear nucleus (VCN) originates within the cochlea of adult and juvenile mammals ([@bib6]; [@bib33]; [@bib66]; Sheperd et al. 1999; [@bib67]; [@bib41]; [@bib16]., [@bib81]) and pre- and posthatched birds ([@bib8]; [@bib7]; [@bib43]). An alteration in VCN spontaneous activity is expected to have an impact on IC electrical activity. In the gerbil, 2-deoxyglucose studies demonstrate that the metabolic activity is decreased in the contralateral lobe of the IC following either conductive hearing loss or SNHL, even in relative silence ([@bib66]). Together, these findings suggest that cochlear ablation, either in infancy or adulthood, results in a significant loss of peripheral action potentials and neurotransmission during the period immediately after ablation, and these factors likely influenced the inhibitory properties we assayed in the cortex.

Partial or total loss of activity in the somatosensory, visual, and auditory systems indicates downregulation of GABAergic transmission, and our data concur with these findings. For example, blocking action potentials by chronically exposing cultured neurons with tetrodotoxin leads to a significant decline in mIPSC amplitudes due to a decrease in the average number of open GABA-gated channels and their inappropriate clustering at the postsynaptic membrane that includes β subunits ([@bib32]). We observed a similar reduction in the amplitudes of sIPSC and mIPSC in SNHL neurons suggesting decreased GABA~A~ receptor function is likely associated with a lower number of GABA~A~ receptors ([@bib52], [@bib53]). The diminished sIPSC and mIPSC and putative unitary IPSC amplitudes in SNHL neurons ([Figs 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}) correspond with a decline in inhibitory conductance in the IC following bilateral SNHL ([@bib69]). It is also possible that decreased inhibitory response amplitudes were due to depolarization of the IPSP reversal potential as shown in the lateral superior olivary and IC neurons ([@bib36]; [@bib69]; [@bib71]), although we did not test this. Similarly, weakened connections between fast-spiking GABAergic interneurons and star pyramidal neurons are observed in L4 of visually deprived animals ([@bib45]). Our observations may additionally explain the reduced amplitude IPSPs when maximum number of afferents are activated ([@bib37]).

Our data also suggest that at the presynaptic level, SNHL neurons appear to release more GABA ([Fig. 1](#fig1){ref-type="fig"}; and increased mIPSCs frequency, results), and this correlates with a significantly enhanced GAD immunoreactivity quantified ultrastructurally at the inhibitory terminals that impinge on L2/3 pyramidal neurons (Sarro E, Kotak VC, Sanes DH, Aoki C, unpublished data). In lieu of an enhanced presynaptic GABA release probaility, it is possible that the altered kinetics in sIPSCs we observe may additionally be caused by postsynaptic GABA~A~ receptor desensitization ([@bib29]), although this hypothesis remains to be tested.

Development and GABAergic Properties
------------------------------------

The strong resemblance of sIPSC characteristics in SNHL neurons with those recorded before hearing onset ([Fig. 6](#fig6){ref-type="fig"}) implies an arrest in the normal expression of GABAergic transmission at pre- and postsynaptic loci. We found that SNHL leads to longer duration sIPSCs ([Fig. 2](#fig2){ref-type="fig"}) and near me-IPSCs ([Fig. 3](#fig3){ref-type="fig"}), which resemble long IPSCs before hearing onset ([Fig. 6](#fig6){ref-type="fig"}). Developmental shortening of IPSCs is consistent with long mIPSCs recorded during early development from rat cerebellar granule cell and mouse cerebellar stellate neurons ([@bib64]; [@bib52], [@bib73]). In stellate neurons, for example, mIPSCs at P11 are long, whereas at P35, they decay 5 times faster ([@bib73]).

The subunit-specific agonists zolpidem for α1 subunits ([@bib58]; [@bib74]; [@bib44]; [@bib60]) and loreclezole for β2/3 subunits ([@bib79]; [@bib2]) target GABA~A~ receptor subunits that affect IPSC kinetics. Both α1 and β2/3 subunits are activated by synaptically released GABA ([@bib1]; [@bib15]; [@bib4]). Functions of these subunits in L2/3 pyramidal neurons can be assayed by the magnitude of effect of these 2 agents, which act to enhance IPSC durations ([Figs 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}, [@bib2]). Importantly, these agents can be used to assess whether the subunit expression undergoes developmental changes in parallel to the alterations in the amplitudes and kinetics of IPSCs. For example, in cerebellar inhibitory synapses, mIPSCs recorded in α1 subunit--deficient mice at P35 are as slow as those at P11 suggesting that lack of α1 subunit insertion in postsynaptic receptors is responsible for the prolonged inhibitory synaptic currents. Also, in recombinant systems, rapid application of GABA to outside-out excised patches generates faster currents with α1β2γ2 than with other subunit combinations ([@bib72]; [@bib23]; [@bib40]; [@bib46]), which agrees with the predominant stoichiometry (α1β2γ2) of the GABA~A~ receptor in mammalian cortex ([@bib34]; [@bib49]; [@bib26]). Similarly, a progressive shortening of mIPSCs in thalamic relay neurons during the 1st postnatal month is accompanied by an increased expression of α1 subunit transcripts and decrease in the α2 transcripts. Further, thalamic organotypic cultured neurons with an overexpressed α1 subunit showed faster mIPSCs ([@bib54]). Similar to the α1 subunit, the β2/3 subunits may emerge during postnatal development. For example, IPSC sensitivity to loreclezole increases across postnatal life in rat dentate granule cells ([@bib30]), rat medial septum/diagonal band neurons ([@bib25]), and mouse cerebellar granule cultured neurons ([@bib55]). In fact, the developmental upregulation of β2/3 subunit function may depend on α1 subunit expression; the effect of loreclezole is compromised in IPSCs from α1 subunit −/− mice ([@bib55]).

Consistent with these studies, our data also suggest that the α1 and β2/3 subunits are upregulated during development. This is shown by the significant augmentation of sIPSCs in control P17--19 neurons by zolpidem and loreclezole and in contrast the inability of these agonists to potentiate sIPSC durations in prehearing animals ([Fig. 6](#fig6){ref-type="fig"}). Similarly, the inability of zolpidem and loreclezole to augment SNHL sIPSCs strongly implies that SNHL may halt the normal expression of the α1 and β2/3 subunits on L2/3 cells that otherwise would impart shorter IPSC kinetics ([Fig. 2](#fig2){ref-type="fig"}, [@bib54]; [@bib3]; [@bib1]; [@bib74]; [@bib23]; [@bib29]; [@bib4]). Significantly lower β2/3 immunogold counts observed in SNHL neurons at the normal postsynaptic membraneous site supports this deduction (Sarro E, Kotak VC, Sanes DH, Aoki C, unpublished data). Importantly, similar to an area-specific expression of the α1 subunits in developing rat neocortex that may be mediated via activity ([@bib57]), the expression and proper distribution of the α1 and β2/3 subunits appear to be regulated by auditory activity.

The prolonged sIPSCs observed in prehearing animals and the inability of the subunit-specific agonists to affect their durations implies that α1 and β2/3 are not predominantly expressed in the ACx before hearing onset. This raises an important question: what other subunits may underlie such long IPSCs that may persist in an absence of acoustically driven activity? It is known that the developmental expression of the α1 subunit mRNA in the cerebellum is very low during early life ([@bib9]; [@bib39]). Other subunits such as α5 ([@bib17]), α2, and α3 are likely to mediate long sIPSCs similar to those found early in development. As a matter of fact, mRNA for α2 and α3 subunits are observed in early development ([@bib39]).

Cortical Excitability and GABAergic Properties
----------------------------------------------

The coadjustments of GABAergic function at pre- and postsynaptic loci are in contrast with the amplified strength of the thalamocortical synapses following SNHL. Decreased probability of glutamate release (miniature excitatory postsynaptic currents \[mEPSCs\]) was accompanied by increased AMPAergic and NMDAergic participation (me-EPSCs) and higher NR2B immunogold counts at the asymmetric synapses ([@bib37]). Coupled with altered membrane properties favoring heightened excitability, the significant decline in postsynaptic GABAergic function may support higher discharge rates and thus alter the network properties of the ACx. [Figure 8](#fig8){ref-type="fig"} shows a diagrammatic sketch of a L2/3 pyramidal SNHL neuron summarizing the present and previous findings. Although this model represents synaptic and biophysical properties following SNHL, it may apply to a range of conditions that decrease sound-evoked activity (e.g., the hair cell loss due to ototoxic drugs, aging, or noise-induced trauma, [@bib63]; [@bib42]). Such weakened inhibition may eventually lead to flawed communication among neurons and a disorganized tonotopy ([@bib31]). For example, even mild to moderate forms of conductive hearing loss produces synaptic modifications within the ACx ([@bib80]), and reduced GABAergic transmission may contribute. The current findings may also explain, in part, the changes that result from partial hair cell damage including the unmasking of excitatory sidebands and discharge characteristics ([@bib28]; [@bib59]; [@bib61]; [@bib76]; [@bib77]). Diminished inhibitory transmission may also contribute to temporal jitter to acoustic cues; for example, both the excitatory synaptic and spike precision are compromised at auditory nerve--bushy cell synapses in the cochlear nucleus of early-onset hearing-impaired mice ([@bib78]). The net effects of such pre- and postsynaptic modifications upon ACx networks and their input--output functions remain to be identified. The overall downscaling of inhibitory gain shown for SNHL neurons may be associated with various clinical conditions such as epilepsy, tinnitus, and presbycusis that are also characterized by reduced GABAergic gain. In addition to the use of implant-based prostheses, attempts to design targeted drugs with specific affinity toward distinct GABA~A~ receptor subunits holds potential to alleviate deficits for the hearing impaired.
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